Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;40(6):1469-1479.
doi: 10.1007/s00345-022-03987-4. Epub 2022 Apr 10.

Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands

Daan J Reesink  1 , Ewoudt M W van de Garde  2   3 , Paul van der Nat  4   5 , Diederik M Somford  6 , Maartje Los  7 , Simon Horenblas  8 , Harm H E van Melick  9 ; Santeon MIBC Study Group
Collaborators, Affiliations

Hospital variation in treatment patterns and oncological outcomes for patients with muscle-invasive and metastatic bladder cancer in the Netherlands

Daan J Reesink et al. World J Urol. 2022 Jun.

Abstract

Purpose: Population-based studies on treatment patterns in oncology and corresponding clinical outcomes can help identify strategies towards optimal value for patients. This study was performed to describe the variation in treatment patterns and major oncological outcomes for muscle-invasive or metastatic bladder cancer (MIBC/mBC) patients in the Netherlands.

Methods: Patients diagnosed with cT2-4aN0-3M0-1 disease between 2008 and 2016 in seven large teaching hospitals in the Netherlands were included. Baseline characteristics, disease stage, intended and definitive treatment, and oncological outcomes were collected. Patients were categorized based on cTNM-stage: (1) cT2-4aN0M0, (2) cT2-4aN1-3M0 and (3) cT4b and/or M1.

Results: The total study population comprised 1853 patients, of which 1303 patients were diagnosed with cT2-4aN0M0 disease. Overall, curative treatment was intended in 81% (range 74-85%, P value = 0.132). Radical cystectomy (RC) and curative radiotherapy (RTx) ranged between hospitals from 42 to 66% and 13 to 27%, respectively (P value < 0.001). For 334 patients staged cT4b and/or M1, frequencies for palliative therapy and best supportive care (no anti-cancer therapy) ranged between hospitals from 20 to 54% and 44 to 71%, respectively (P value < 0.001). There was no association between hospital site and overall survival (OS) in a univariable and multivariable Cox regression for survival analysis (after adjusting for age and cT-stage), for all three cTNM-groups. Neoadjuvant or induction chemotherapy (NAIC) utilization rates before RC ranged from 8 to 38% (P value < 0.001).

Conclusions: There is large inter-hospital variation in treatment intent in MIBC/mBC patients. This variation does not seem to translate to differences in overall survival rates. There is an ongoing trend of increased use of RC. Utilisation of NAIC is relatively low considering European guideline recommendations.

Keywords: Bladder cancer; Metastatic; Muscle invasive; Outcomes; Treatment patterns.

PubMed Disclaimer

References

    1. van der Vlies E, Los M, Stijns PEF, van Hengel M, Blaauw NMS, Bos WJW et al (2020) Preoperative frailty and outcome in patients undergoing radical cystectomy. BJU Int 126:388–395. https://doi.org/10.1111/bju.15132 - DOI - PubMed
    1. Schrag D, Mitra N, Xu F, Rabbani F, Bach PB, Herr H et al (2005) Cystectomy for muscle-invasive bladder cancer: Patterns and outcomes of care in the medicare population. Urology 65:1118–1125. https://doi.org/10.1016/j.urology.2004.12.029 - DOI - PubMed
    1. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866. https://doi.org/10.1056/NEJMoa022148 - DOI - PubMed
    1. Vale CL (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 48:202–206. https://doi.org/10.1016/j.eururo.2005.04.006 - DOI
    1. Griffiths G (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171–2177. https://doi.org/10.1200/JCO.2010.32.3139 - DOI - PubMed

Grants and funding

LinkOut - more resources